Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The RESOLVE-DVT study is a randomized single-center pilot study to determine the effects of
hydroxyethylrutoside (Venoruton) on aspects of deep vein thrombosis (DVT) resolution
associated with post-thrombotic syndrome (PTS). Based on these results, the investigators
will estimate its potential as a preventive therapy for PTS.
Eligible consenting patients who develop an acute, objectively confirmed DVT will be
randomized and equally allocated to two trial arms, either the treatment group (Venoruton
tablet 500 mg twice daily) or the control group (usual care). The pilot trial consists of 5
study contacts over 12 weeks at which outcome assessment is performed: inclusion, 1 week, 4
weeks, 8 weeks, 12 weeks. Treatment allocation is masked for outcome assessors, but not for
patients.